Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia

References

• Vos T, Allen C, Arora M., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
   PubMed Web of Science ®Google Scholar
• Organization UNWH. Iron Deficiency Anaemia: Assessment, Prevention and Control: A Guide for Programme Managers. World Health Organization; 2001.
   Google Scholar
• Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Supplement 1):S4–S8. doi:10.2215/CJN.01490506
   PubMed Web of Science ®Google Scholar
• De Benoist B, Cogswell M, Egli I, et al. Worldwide prevalence of anaemia 1993-2005. WHO Global Database of anaemia; 2008.
   Google Scholar
• Das SN, Devi A, Mohanta BB, et al. Oral versus intravenous iron therapy in iron deficiency anemia: an observational study. J Family Med Primary Care. 2020;9(7):3619. doi:10.4103/jfmpc.jfmpc_559_20
   PubMedGoogle Scholar
• Giordano G, Napolitano M, Di Battista V, et al. Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study. Ann Hematol. 2020;1;1–7.
   Google Scholar
• Alquaiz A-JM, Khoja TA, Alsharif A, et al. Prevalence and correlates of anaemia in adolescents in Riyadh city, Kingdom of Saudi Arabia. Public Health Nutr. 2015;18(17):3192–3200. doi:10.1017/S1368980015001214
   PubMed Web of Science ®Google Scholar
• Abalkhail B, Shawky S. Prevalence of daily breakfast intake, iron deficiency anaemia and awareness of being anaemic among Saudi school students. Int J Food Sci Nutr. 2002;53(6):519–528. doi:10.1080/09637480220164370
   PubMed Web of Science ®Google Scholar
• Gari MA. Prevalence of iron deficiency anemia among female elementary school children in Northern Jeddah, Saudi Arabia. J King Abdulaziz Univ Med Sci. 2008;15(1):63–75. doi:10.4197/Med.15-1.6
   Google Scholar
• Al Hifzi I, Pejaver RK, Qureshi I. Screening for iron deficiency anemia in a well baby clinic. Ann Saudi Med. 1996;16(6):622–624. doi:10.5144/0256-4947.1996.622
   PubMed Web of Science ®Google Scholar
• AlSheikh MH. Prevalence and risk factors of iron-deficiency anemia in Saudi female medical students. Prevalence. 2018;7(3):148–152.
   Google Scholar
• Al Hawsawi ZM, Al-Rehali SA, Mahros AM, et al. High prevalence of iron deficiency anemia in infants attending a well-baby clinic in northwestern Saudi Arabia. Saudi Med J. 2015;36(9):1067. doi:10.15537/smj.2015.9.11844
   PubMed Web of Science ®Google Scholar
• Owaidah T, Al-Numair N, Al-Suliman A, et al. Iron deficiency and iron deficiency anemia are common epidemiological conditions in Saudi Arabia: report of the National Epidemiological Survey. Anemia. 2020;2020:6642568. doi:10.1155/2020/6642568
   PubMed Web of Science ®Google Scholar
• Crichton RR, Danielson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. UNI-MED-Verl; 2008.
   Google Scholar
• Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):267–278. doi:10.1097/01.AOG.0000275286.03283.18
   PubMed Web of Science ®Google Scholar
• Mulder MB, van den Hoek HL, Birnie E, et al. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer(®)) versus ferric carboxy-maltose (Ferinject(®)). Br J Clin Pharmacol. 2019;85(2):385–392.
   PubMed Web of Science ®Google Scholar
• Christoph P, Schuller C, Studer H, et al. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. J Perinat Med. 2012;40(5):469–474.
   PubMed Web of Science ®Google Scholar
• Fletes R, Lazarus JM, Gage J, et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001;37(4):743–749. doi:10.1016/S0272-6386(01)80123-2
   PubMed Web of Science ®Google Scholar
• Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013;88(2):97–101. doi:10.1002/ajh.23354
   PubMed Web of Science ®Google Scholar
• Das SN, Devi A, Mohanta BB, et al. Oral versus intravenous iron therapy in iron deficiency anemia: an observational study. J Family Med Prim Care. 2020;9(7):3619–3622.
   PubMedGoogle Scholar
• Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;1;347.
   Google Scholar
• Tagboto S, Cropper L, Turner J, et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject®) on anaemia in a pre‐dialysis population of chronic. Kidney Dis Patients J Renal Care. 2009;35(1):18–23.
   PubMedGoogle Scholar
• Laso-Morales MJ, Vives R, Vallejo-Tarrat A, et al. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial. Trials. 2019;20(1):23. doi:10.1186/s13063-018-3125-2
   PubMed Web of Science ®Google Scholar
• Abdelazim IA, Nusair B, Svetlana S, et al. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. Arch Gynecol Obstet. 2018;298(6):1231–1232. doi:10.1007/s00404-018-4943-x
   PubMed Web of Science ®Google Scholar
• Aarts E, Van Wageningen B, Janssen I, et al. Prevalence of anemia and related deficiencies in the first year following laparoscopic gastric bypass for morbid obesity. J Obes. 2012;2012:85.
   Google Scholar
• Smith CD, Herkes SB, Behrns KE, et al. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 1993;218(1):91–96. doi:10.1097/00000658-199307000-00014
   PubMed Web of Science ®Google Scholar
• Salgado W, Modotti C, Nonino CB, et al. Anemia and iron deficiency before and after bariatric surgery. Surg Obes Relat Dis. 2014;10(1):49–54. doi:10.1016/j.soard.2013.06.012
   PubMed Web of Science ®Google Scholar
• Schijns W, Boerboom A, de Bruyn Kops M, et al. A randomized controlled trial comparing oral and intravenous iron supplementation after Roux-en-Y gastric bypass surgery. Clinical Nutrition. 2020;39(12):3779–3785. doi:10.1016/j.clnu.2020.04.010
   PubMed Web of Science ®Google Scholar
• Malone M, Barish C, He A, et al. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients. Obes Surg. 2013;23(9):1413–1420. doi:10.1007/s11695-013-0939-6
   PubMed Web of Science ®Google Scholar
• Schafer AI. Thrombocytosis and thrombocythemia. Blood Rev. 2001;15(4):159–166. doi:10.1054/blre.2001.0162
   PubMed Web of Science ®Google Scholar
• Emrich IE, Lizzi F, Siegel JD, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study. BMC Med. 2020;18(1):178. doi:10.1186/s12916-020-01643-5
   PubMed Web of Science ®Google Scholar
• Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266–275. doi:10.1097/MNH.0000000000000329
   PubMed Web of Science ®Google Scholar
• Fang W, McMahon LP, Bloom S, et al. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 2019;3(5):438–440. doi:10.1002/jgh3.12150
   PubMed Web of Science ®Google Scholar
• Wolf M, Chertow GM, Macdougall IC, et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23):23. doi:10.1172/jci.insight.124486
   Web of Science ®Google Scholar
• Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435.e1–e7. doi:10.1016/j.ajog.2008.07.046
   PubMed Web of Science ®Google Scholar
• Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstetrics. 2008;101(1):67–73. doi:10.1016/j.ijgo.2007.10.009
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2Part 1):267–278.
   PubMedGoogle Scholar
• Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrology Dialysis Transplantation. 2011;26(5):1599–1607. doi:10.1093/ndt/gfq613
   PubMed Web of Science ®Google Scholar
• Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial. Official j Am College Gastroenterol. 2008;103(5):1182–1192. doi:10.1111/j.1572-0241.2007.01744.x
   PubMed Web of Science ®Google Scholar